- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,800 | +4,98 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +5,08 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| BIOMERIEUX | 83,20 | +3,55 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,849 | +3,41 % | Morning Market Movers: Bio Green Med Solution, Solidion Technology, Indaptus Therapeutics, Merlin, Inc. See Big Swings | BEIJING (dpa-AFX) - At 7:20 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ANAPTYSBIO | 42,500 | +3,16 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli... ► Artikel lesen | |
| GENUS | 26,200 | +1,55 % | Genus PLC - Annual Report and Annual General Meeting | ||
| MEIRAGTX | 9,700 | +3,19 % | MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors | LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of... ► Artikel lesen | |
| AKESO | 12,280 | +1,49 % | Akeso, Inc.: Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer | HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,580 | +0,64 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| ABIONYX PHARMA | 1,532 | +4,93 % | ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply | CER-001: a distinctive manufacturing challenge to produce a full-length recombinant human apoA-I, a 243-amino-acid protein to form a biomimetic HDL particle A strategic partnership including... ► Artikel lesen | |
| MAAT PHARMA | 0,891 | -1,11 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
07.10.2026 / 14:10 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,056 | 0,00 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | +3,69 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | +2,45 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen |
ISR IMMUNE SYSTEM REGULATION HOLDING AB gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.